Androgen Deprivation Therapy and SARS-CoV-2 Infection in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis

Creative Commons License

Semiz H. S., Arayıcı M. E., Ellidokuz H.

Eurasian Journal of Medical Investigation, vol.6, no.3, pp.273-278, 2022 (Peer-Reviewed Journal)


Objectives: The main treatment for metastatic prostate cancer is androgen deprivation therapy. The relationship between ADT and SARSCoV-2 virus was intensively investigated since the COVID 19 pandemic began. To perform a meta-analysis to evaluate the effect of androgen deprivation therapy (ADT) on COVID-19 in patients with prostate cancer. Methods: On January 11th, a comprehensive literature search was conducted following PRISMA guidelines in the PubMed, Scopus, Embase, and Web of Science databases, and an update was conducted on January 24 for this search. Results: Eight papers were included for systematic review. Five studies were suitable for meta-analysis. The incidence of SARS-CoV-2 infection among patients who were receiving ADT was 3.0%. ADT was not associated with a lower incidence of SARS-CoV-2 infection (95% CI: 0.56-1.58, RR = 0.94, p=.91; I2 = 60%, p=.03). Mortality was around 28% and there was no significant relationship between ADT use and mortality (95% CI: 0.61-1.69, RR = 1.01, p=.96). Conclusion: It is difficult to say that there is a relationship between use of ADT and the risk of death due to COVID-19 infection. But there is also no evidence to suggest that ADT causes the risk of death from COVID-19. Keywords: Androgen deprivation therapy, prostate cancer, SARS-CoV-2